Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) has issued an update.
On March 12, 2026, Dr. Reddy’s Laboratories allotted 10,275 fully paid equity shares of Re.1 each to eligible employees following the exercise of stock options under its 2002 Employee Stock Options Scheme and 2007 ADR Stock Option Scheme. The issue marginally increases the company’s paid-up equity share capital to 83,46,53,295 shares, with the new stock ranking pari passu with existing shares, signaling continued reliance on share-based compensation to align employee incentives with shareholder interests.
The allotment, disclosed under India’s SEBI listing and share-based benefit regulations and notified simultaneously to Indian and U.S. exchanges, underscores Dr. Reddy’s ongoing use of equity-linked incentives across both domestic and ADR platforms. While the quantum of shares is small relative to total capital and thus minimally dilutive, it highlights steady execution of long-standing ESOP programs as part of the company’s talent retention and governance framework.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company headquartered in Hyderabad, Telangana, with its equity shares listed on BSE and the National Stock Exchange of India and its American Depositary Receipts traded on the New York Stock Exchange and NSE IFSC. The company operates in the branded and generic formulations space, with a focus on regulated markets and broad access to affordable medicines for global healthcare consumers.
Average Trading Volume: 1,717,328
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.99B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.